Loading patent…
AssigneeYeda Research and Development Co. Ltd.
InventorsZelig Eshhar, Eran Elinav
Estimating the term…
A redirected Treg cell is endowed with specificity toward a selected target antigen or ligand. The cell contains a chimeric receptor polypeptide that is expressed in a single, continuous chain, with an extracellular recognition region displayed on the surface of the cell, a transmembrane region and an intracellular signaling region. The extracellular recognition region is specific for the selected target antigen or ligand. The intracellular signaling region includes a combination of T-cell signaling polypeptide moieties, which combination, upon binding of the extracellular recognition region to the selected target antigen or ligand, triggers activation of the redirected Treg cells to cause suppression of T-cell mediated immunity. Such redirected Treg cells may be used to suppress undesired activity of T effector cells thereby mediating an immune or inflammatory response. They are particularly useful in treating T effector cell-mediated diseases, such as inflammatory bowel disease, transplant rejection and GVH disease.
A redirected regulatory T lymphocyte (Treg cell) endowed with specificity toward a selected target antigen or ligand, which cell comprises a chimeric nucleic acid that encodes a chimeric receptor polypeptide that comprises, expressed in a single, continuous chain, an extracellular recognition region, a transmembrane region and an intracellular signaling region, and is expressed in the redirected Treg cell so as to display the extracellular region on the cell surface, wherein
A chimeric DNA molecule comprising:
Dependencies are inferred from the claim text.